Total platelet donation count and donation frequency are determinants of plateletpheresis‐associated lymphopenia

Plateletpheresis using a leukocyte reduction system (LRS) traps donor WBCs in the LRS chamber, which may lead to lymphopenia, especially in frequent plateletpheresis donors. It seems plausible that this might cause adverse effects. However, current knowledge about potential confounders and donor health impacts is incomplete.

[1]  Norbert Ahrens,et al.  R-Skript Leukopenie.R v1 , 2021, protocols.io.

[2]  J. Gorlin.  Commentary on Zhao et al., “Frequent platelet donations is associated with lymphopenia, and risk of infections: A nationwide cohort study” , 2021, Transfusion.

[3]  P. Dickman,et al.  Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study , 2020, Transfusion.

[4]  Nikolas I. Krieger,et al.  Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population , 2019, JAMA network open.

[5]  D. Neuberg,et al.  Severe CD4+ T‐cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus , 2019, Transfusion.

[6]  D. Neuberg,et al.  CD4+ T‐cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year , 2019, Transfusion.

[7]  D. Neuberg,et al.  Plateletpheresis-associated lymphopenia in frequent platelet donors. , 2019, Blood.

[8]  J. Delisle,et al.  Leukoreduction system chambers are a reliable cellular source for the manufacturing of T‐cell therapeutics , 2018, Transfusion.

[9]  Stig Egil Bojesen,et al.  Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study , 2018, PLoS medicine.

[10]  M. Avci-Adali,et al.  Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility , 2018, Front. Bioeng. Biotechnol..

[11]  E. Holler,et al.  Granulocytapheresis with modified fluid gelatin versus high‐molecular‐weight hydroxyethyl starch: a matched‐pair analysis , 2017, Transfusion.

[12]  E. Holler,et al.  Technical comparison of four different extracorporeal photopheresis systems , 2016, Transfusion.

[13]  F. Formiga,et al.  Lymphopenia as prognostic factor for mortality and hospital length of stay for elderly hospitalized patients , 2016, Aging Clinical and Experimental Research.

[14]  F. Ansaldi,et al.  Immunomodulation due to plasma or plasma–platelet apheresis donation: Events occurring during donation procedures , 2015, Journal of clinical apheresis.

[15]  F. Ansaldi,et al.  Transient transforming growth factor β1 modulation in monocytes and natural killer cells following plasma or plasma-platelet apheresis donation procedures. , 2015, Blood transfusion = Trasfusione del sangue.

[16]  Hong Chen,et al.  Blood compatible materials: state of the art. , 2014, Journal of materials chemistry. B.

[17]  L. Peng,et al.  Lymphopenia and poor performance status as major predictors for infections among residents in long-term care facilities (LTCFs): a prospective cohort study. , 2014, Archives of gerontology and geriatrics.

[18]  F. Ansaldi,et al.  A possible role of soluble HLA-I molecule in the immunomodulatory effects of therapeutic apheresis. , 2014, Blood transfusion = Trasfusione del sangue.

[19]  Sinyoung Kim,et al.  [Analysis of characteristics of mononuclear cells remaining in the leukoreduction system chamber of Trima Accel and their differentiation into dendritic cells]. , 2009, The Korean journal of laboratory medicine.

[20]  R. Strauss.  Risks of clinically significant thrombocytopenia and/or lymphocytopenia in donors after multiple plateletpheresis collections , 2008, Transfusion.

[21]  J. Winters,et al.  The effect of double‐ and triple‐apheresis platelet product donation on apheresis donor platelet and white blood cell counts , 2008, Transfusion.

[22]  T. Weidinger,et al.  Recovery of white blood cells and platelets from leukoreduction system chambers of Trima Accel and COBE Spectra plateletpheresis devices , 2007, Transfusion.

[23]  N. Pineault,et al.  Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells , 2007, Transfusion.

[24]  D. Loew,et al.  Plateletpheresis does not cause long‐standing platelet‐derived growth factor release into the donor blood , 2005, Transfusion.

[25]  F. Trepel,et al.  Number and distribution of lymphocytes in man. A critical analysis , 1974, Klinische Wochenschrift.

[26]  O. Pickeral,et al.  Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. , 2003, Blood.

[27]  R. Westendorp,et al.  Lymphocyte Count and Mortality Risk in Older Persons. The Leiden 85‐Plus Study , 2003, Journal of the American Geriatrics Society.

[28]  S. Ferrone,et al.  Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. , 2000, International immunology.

[29]  R. Moog,et al.  White cell reduction during plateletpheresis: a comparison of three blood cell separators , 1999, Transfusion.

[30]  H. Eichler,et al.  Safety issues of plateletpheresis: comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil‐platelet aggregates , 1999, Transfusion.

[31]  I. Karadoğan,et al.  Automated plateletpheresis does not cause an increase in platelet activation in volunteer donors. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[32]  R. Strauss.  Effects on donors of repeated leukocyte losses during plateletpheresis , 1994, Journal of clinical apheresis.

[33]  J. Hall,et al.  In vitro study of immunologic changes in long‐term cytapheresis donors , 1991, Journal of clinical apheresis.

[34]  H. Shapiro,et al.  Effects of frequent and sustained plateletapheresis on peripheral blood mononuclear cell populations and lymphocyte functions of normal volunteer donors , 1986, Transfusion.

[35]  Bradley S. Bender,et al.  Absolute Peripheral Blood Lymphocyte Count and Subsequent Mortality of Elderly Men , 1986, Journal of the American Geriatrics Society.

[36]  B. Brozović,et al.  Lymphocytopenia in donors undergoing regular platelet apheresis with cell separators. , 1985, Clinical and laboratory haematology.

[37]  R. Strauss.  Apheresis donor safety ‐ changes in humoral and cellular immunity , 1984, Journal of clinical apheresis.

[38]  P. Horan,et al.  Long‐Term Follow‐Up of Donors Cytapheresed More Than 50 Times , 1983, Vox sanguinis.

[39]  R. Strauss,et al.  Panel V: Cellular depletion by apheresis , 1983 .

[40]  R. Strauss,et al.  Cellular depletion by apheresis. , 1983, Journal of clinical apheresis.

[41]  Senhauser Da,et al.  Immune system changes in cytapheresis donors. , 1982 .

[42]  J. Neff,et al.  Immune system changes in cytapheresis donors , 1982, Transfusion.

[43]  R. Strauss,et al.  The safety of weekly plateletpheresis: effect on the donors' lymphocyte population , 1981, Transfusion.

[44]  M. Kuroki,et al.  Age-related changes in the subsets and functions of human T lymphocytes. , 1978, Journal of immunology.